The Lancet Respiratory Medicine Published Study Shows Ensartinib Holds Promise as a New Treatment Option for ALK-positive Non-Small Cell Lung Cancer

Xcovery Holdings, Inc., an oncology-focused biopharmaceutical company, today announced that ensartinib, the company’s lead drug candidate, demonstrated efficacy and safety in patients with crizotinib-refractory, anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC), including those with brain metastases. The peer-reviewed manuscript of the study, “Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial” was published online in The Lancet Respiratory Medicine.

Link:
businesswire.com/news/home/20191017006005/en/Lancet-Respiratory-Medicine-Published-Study-Shows-Ensartinib